- HWI group
- Media centre
- Artificial Intelligence
Innovative Services for Pharma, Biotech & Medtech
The HWI group offers a broad range of individual and specialised pharmaceutical services for the pharma, biotech and medtech sector, particularly for active ingredients, medicinal products and medical devices. Benefit from our long-standing experience in laboratory services, vigilance and quality services, drug development as well as regulatory affairs services.
AIQNET— Medical data ecosystem
HWI is part of a consortium that is one of the winners of the AI Innovation Competition by the Federal Ministry for Economic Affairs and Energy in 2019.
A digital ecosystem called AIQNET is being built collaboratively. The aim of the platform is to structure and use medical and clinical data in compliance with legal and ethical framework conditions. For more information – read here.
Vigilance & Quality
The active pharmaceutical ingredient (API) is at the heart of our risk-based development. Its properties have a critical influence on the quality of the product. In our ultra-modern clean rooms we can also work with highly potent active ingredients. By using statistical design of experiment (DoE) we offer an efficient pharmaceutical development that completely fulfils the requirements of quality by design.
Until further notice, the HWI group will take the following measures to ensure that our services are maintained for you.
Click on "Read more" and read the measures in detail.
30 years ago: On January 8th, 1991, the company was founded by Dr. Stefan Wissel and Prof. Dr. Hanns Häberlein. The two university friends created the name HWI from the first letters of their last names.
As of January 1st, 2021, Dr Frank Böttcher will be appointed to the management team of HWI pharma services GmbH and will strengthen the current management team of Dr Stefan Wissel and Dr Melanie Kerst.
You will find further information in our press release.
Stay up to date:
Innovation and Technology Support
Monday - Friday
08:00 - 17:00 o´clock